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Microglia constitute the powerhouse of the innate immune system in the brain. It is
now widely accepted that they are monocytic-derived cells that infiltrate the developing
brain at the early embryonic stages, and acquire a resting phenotype characterized
by the presence of dense branching processes, called ramifications. Microglia use
these dynamic ramifications as sentinels to sense and detect any occurring alteration
in brain homeostasis. Once a danger signal is detected, such as molecular factors
associated to brain damage or infection, they get activated by acquiring a less ramified
phenotype, and mount adequate responses that range from phagocyting cell debris to
secreting inflammatory and trophic factors. Here, we review the origin of microglia and
we summarize the main molecular signals involved in controlling their function under
physiological conditions. In addition, their implication in the pathogenesis of multiple
sclerosis and stress is discussed.
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THE ORIGIN OF MICROGLIA
The name microglia is derived from micro (i.e., small) and glia (i.e., glue). Resident microglia
are mononuclear phagocytes and constitute the main resident immune cell population of the
brain, representing up to 10% of the cells in the brain (Soulet and Rivest, 2008). Microglia were
firstly visualized and identified in 1919 (reviewed in Tremblay et al., 2011, 2015), and despite the
extensive research conducted since then, the origin of microglia is still elusive. Several different
origins have been proposed for these cells. For instance, it has been proposed that microglia are
derived from progenitors that originate from the neuroectoderm and/or the mesoderm, which
colonize the brain from the early embryonic stage and throughout the fetal development stage
(Chan et al., 2007; Soulet and Rivest, 2008). In addition, it has been proposed that microglia are
derived from circulating blood monocytes, especially from the late gestational stage throughout
the early post-natal stage (Chan et al., 2007). Despite these different proposed origins, a consensus
view holds that microglia are derived from myeloid progenitors that infiltrate the brain during
the different brain developmental stages. It is noteworthy to mention that ∼95% of the microglia
population are generated post-natally and more precisely after the formation of the blood–brain
barrier (BBB). Once again, how these cells are maintained in the adult brain during lifespan is a
matter of debate. One major view suggests that microglia are maintained in the adult brain through
either a self-renewal process or by the expansion of a reservoir of progenitors that have colonized
the developing brain (Soulet and Rivest, 2008). Another major view suggests that microglia are
maintained in the adult brain through a turnover process by the differentiation of precursors
present in the blood circulation, namely monocytes, that infiltrate the adult brain (Soulet and
Rivest, 2008). However, the relevance of this turnover process under physiological condition is still
unclear.
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Regardless their exact origin, it is widely accepted now that
once microglial progenitors have infiltrated the brain, they adopt
a highly ramified morphology (Kettenmann et al., 2011). Early
reports suggested that this phenotype translates a resting state
of these cells. This ramified phenotype is characterized by the
presence of long cellular branching processes and a small cell
body. While the cellular branches are constantly moving, the
cell body remains in place. Recent findings revolutionized our
understating for the function of microglia by showing that
these cells are never resting and are continuously patrolling
the brain in quest of any alteration in cerebral homeostasis
(Kettenmann et al., 2013; Figure 1). More precisely, these
recent findings showed that microglia use their dynamic and
motile cellular processes as sentinels to survey and scan the
microenvironment within their vicinity to detect any occurring
change in brain homeostasis (Kettenmann et al., 2013). Microglia
rapidly get activated in the presence of a threat and they
adopt a less ramified and more amoeboid phenotype with a
large soma. Following activation, these cells rapidly mount
appropriate responses in order to deal with the emerging
threat, which could range from phagocytosis to the release
of molecular mediators, including immune and non-immune
factors (Kettenmann et al., 2013; Lampron et al., 2013a). The
new technical advances, especially intravital two-photon imaging
in live animals, shed the light on the fascinating nature of
microglia and outlined a more sophisticated role fulfilled by
these cells in maintaining the brain tissue integrity under both
physiological and pathophysiological conditions, by detecting
both non-pathological- and pathological-derived molecular
cues (Davalos et al., 2005; Nimmerjahn et al., 2005). These
new studies showed for instance that microglia continuously
scan the microenvironment within their vicinity by accurately
and significantly modulating the length and the direction
of their processes without detecting significant movement of
their cell bodies. Under physiological conditions, these studies
revealed how microglia through their processes make what
seem to be specific and repeated cell–cell contacts, namely
with neurons, astrocytes, and endothelial cells (Nimmerjahn
et al., 2005; Figure 1). These functions are potentiated under
pathophysiological conditions, where a focal and limited laser-
induced cerebral damage stimulated the extension of microglial
cell processes toward the injury site in few minutes (Davalos
et al., 2005). In addition, even microglia that were not in a direct
contact with the damaged area detected the damage, which led
to their rapid mobilization toward the injury site (Davalos et al.,
2005). Taken together, these reports highlight the dynamic nature
of microglia and new insights into their functions.
SIGNALING IN MICROGLIA
Microglia are highly dynamic and undergo extreme remodeling
process throughout lifespan. For example, it has been suggested
that the concerted movements of microglial cell processes could
survey the entire brain every couple of hours (Nimmerjahn
et al., 2005). Importantly, this behavior requires a tight controlled
regulation of the movement of cell processes, cell motility, cell
morphology, phagocytosis, immune functions, and the secretion
of molecular mediators. These functions are tightly and precisely
controlled by several signaling pathways (Figure 2). Here, we will
briefly present major signaling pathways that play essential roles
in controlling key functions of microglia.
Pattern Recognition Receptor Signaling
Being the major line of defense in the brain, microglia express
several receptors involved in the control of innate immune
functions, especially the pattern recognition receptors (PRRs)
that regroup three major receptor families, toll-like receptors
(TLRs), nucleotide-binding oligomerization domain (nod)-like
receptors (NLRs), and the retinoic acid-inducible gene-1 (RIG1)-
like receptors (RLRs). These receptors recognize specific ligands,
or “patterns,” called pathogen-associated molecular patterns
(PAMPs) and danger-associated molecular patterns (DAMPs).
These patterns include protein molecules, such as exogenous
peptidoglycans and endogenous heat shock proteins, and non-
protein molecules, such as adenosine triphosphate (ATP) and
nucleic acid molecules (Kumar et al., 2011). Activation of these
receptors induces specific signaling pathways that are involved in
modulating microglial functions. TLR activation stimulates the
recruitment of specific intracellular adaptor proteins, namely the
myeloid differentiation primary response gene-88 (Myd88) that
leads mainly to the induction of nuclear factor-kappa B (NF-
κB) signaling pathway, and toll/interleukin-1 receptor (TIR)-
domain-containing adapter-inducing interferon-β (TRIF) that
leads mainly to the induction of interferon regulatory factor-
3 (IRF3) signaling pathway. It is noteworthy to mention that
among the 11 TLRs in humans and 13 in rodents, only TLR3
and TLR4 seem to signal via TRIF (Rivest, 2009; Lampron
et al., 2013a). Until now, 21 NLRs have been identified, among
which NLR pyrin domain containing (NLRP)1/2/3/6/10 and
NOD1/2 are highly expressed in microglia (Rosenzweig et al.,
2011). NLRP3 and NOD2 are the most studied receptors.
NLRP3 activation mediates its oligomerization and stimulates
the formation of a caspase-1 containing inflammasome that
trigger the production of the active form of interleukine-
1β (IL1β), which in turn activates downstream signaling
pathways (Zambetti et al., 2012). On the other hand, NOD2
activation has been shown to stimulate the recruitment of the
adaptor protein receptor-interacting serine/threonine-protein
kinase-2 (RICK) that leads mainly to the induction of NF-κB
signaling pathway (Ribes et al., 2012). Finally, RLR activation
stimulates the recruitment of intracellular adaptor proteins,
namely mitochondrial antiviral-signaling protein (MAVS) and
tumor necrosis factor (TNF) receptor associated factor (TRAF),
both of which trigger NF-κB signaling pathway (Yoneyama and
Fujita, 2010). In addition, triggering RLRs could lead to the
induction of IRF3 signaling pathway (Yoneyama and Fujita,
2010). In summary, PRR signal transduction converges mainly
on two major signaling pathways, namely NF-κB and IRF3.
Cytokine Receptor Signaling
Microglia express a wide range of cytokine receptors that
play a crucial role in modulating microglial cell function.
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FIGURE 1 | The physiological role of microglia. The neurovascular unit (NVU), which is constituted of tightly sealed endothelial cells, basal lamina, pericytes,
astrocyte-endfeet, microglia, and neurons, plays a central role in maintaining brain homeostasis and functioning. In the non-neuropathological conditions, microglia
use their dynamic processes to constantly survey and screen the microenvironment within the NVU. Microglia are fully equipped to detect a wide range of signals
associated to an altered brain homeostasis. In addition, they actively and dynamically communicate with neurons and play an important role in supporting their
functions. Importantly, their physiological role in the intact brain can be altered by several intrinsic factors, such as aging, epigenetics, and genetics. This figure has
been adapted from ElAli and Rivest (2015).
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FIGURE 2 | Microglial signaling and function. A diagram illustrating the main receptor-mediated signaling associated with respective microglial cellular functions.
They also produce a large repertoire of cytokines that are
essential in mediating cell functions. Among these cytokines,
TNFα, transforming growth factor-β (TGFβ), and interleukin
signaling pathways play major roles. Microglia express both
TNF receptor subtypes, TNF receptor 1 (TNFR1/p55) and
TNF receptor 2 (TNFR2/p75), and are, in parallel, a major
source of TNFα in the brain (Dopp et al., 1997). It has been
demonstrated that TNFR1 has a higher binding activity for
soluble TNFα compared to TNFR2. On the other hand, TNFR2
has higher affinity to the membrane-anchored TNFα, which
has been shown to play an important role in cell crosstalk
(Veroni et al., 2010). Although both receptors have similar
extracellular domains, their intracellular domains are structurally
quite different, which translate the capacity of both receptors
to trigger distinct and overlapping signaling pathways. TNFR1
and TNFR2 activation stimulates the recruitment of intracellular
adaptor proteins that mediate the activation of downstream
signaling pathways (MacEwan, 2002). Among these adaptor
proteins, TNF receptor-associating factors (TRAFs) play an
important role in orchestrating the formation of an intracellular
signaling complex (MacEwan, 2002). Activation of both receptors
triggers mainly the NF-κB signaling pathway (Sriram et al.,
2006). Interestingly, several reports have demonstrated that
TNFR1 exacerbates the inflammation (Longhi et al., 2013),
whereas TNFR2 is neuroprotective (Marchetti et al., 2004). TNFR
activation increases the release of TNFα by microglia, which
creates a positive autocrine regulatory mechanism that actively
participates in microglial cell activation (Nadeau and Rivest,
2000; Kuno et al., 2005).
In contrast to TNFα that plays an important role in
potentiating microglial pro-inflammatory responses, TGFβ has
been shown to play a role in counter-regulating these responses
(Suzumura et al., 1993). TGFβ is a multifunctional cytokine
that binds TGFβ receptor type II (TGFRII) and stimulates
the recruitment of TGFβ receptor type I (TGFRI). Initially,
this cytokine is released as inactive complex, from which the
active form is released through different processes (Feng and
Derynck, 2005). Interestingly, the CD36 receptor, which is
abundantly expressed on microglia (El Khoury et al., 2003),
has been shown to contribute in such an activation process
(Yehualaeshet et al., 1999). Upon activation, the TGFRI/RII
complex receptor triggers the formation of Small and Mothers
Against Decaplentaplegic-2/3/4 (SMAD-2/3/4) protein complex
that translocates into the nucleus to regulate the expression
of several target genes (Feng and Derynck, 2005). In parallel,
TGFβ mediates its effects through another signaling pathway,
independently of SMADs, which results in the activation of
mitogen-activated protein kinase (MAPK) and Rho GTPases
signaling pathways (Engel et al., 1999). TGFβ signaling pathway
has also been shown to reduce the production of IL6, IFNγ, and
several chemokines, namely monocyte chemoattractant protein-
1 [MCP1; i.e., chemokine ligand 2 (CCL2); Letterio and Roberts,
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1998] as well as the production of nitric oxide (NO) and the
formation of reactive oxygen species (ROS; Vodovotz et al.,
1993).
Microglia express several IL receptors (ILRs), namely IL1Rs
[e.g., IL1 type I receptor (IL1RI), IL1 type II receptor (IL1RII),
and IL1 receptor accessory protein (IL1RAcP)], IL5R, IL6R,
IL8R, IL9R, IL10R, IL12R, IL13R, and IL15R. IL1β and IL6
play particularly important roles in the microglial cell function.
IL1β signaling pathway potentiates microglial pro-inflammatory
responses. This cytokine is essentially produced in the early
stages of the innate immune response engagement, in response
to TLR/Myd88/NF-κB activation (Herx et al., 2000). IL1β is
initially produced as an inactive protein, from which the active
form is generated via a proteolytic process that includes the
formation of an inflammasome (John et al., 2005). IL1β activates
a receptor complex formed by IL1RI and IL1RAP (Steinman,
2013), thus inducing NF-κB signaling pathway (Spörri et al.,
2001). IL6 is considered as a pro-inflammatory cytokine that
upon binding IL6R stimulates the recruitment of gp130 receptor
(Erta et al., 2012). The receptor complex activates several
intracellular signaling pathways, namely signal transducer and
activator of transcription (STAT) pathway, MAPK pathway, and
phosphatidyl inositol-3 kinase (PI3K) pathway (Erta et al., 2012).
The role of IL6 in the brain is complex and not yet completely
understood. Finally, IL4 and IL10 are potent anti-inflammatory
molecules that have been shown to deeply affect microglial cell
function (Ledeboer et al., 2000).
Chemokine Receptor Signaling
Chemokines are small chemotaxic cytokines that possess
the ability to induce chemotaxis in nearby responsive cells.
Chemokines are a large family of molecules that are characterized
by the presence of conserved cysteine residues in their N-
terminal sequences. Based on the spacing of their first two
cysteine residues, they are classified into four distinct subgroups,
C chemokines (i.e., one N-terminal cysteine), CC chemokines
(i.e., two adjacent N-terminal cysteines), CXC chemokines (i.e.,
one amino acid between the two N-terminal cysteines), and
finally CX3C chemokines (i.e., three amino acids between the two
N-terminal cysteines; Fernandez and Lolis, 2002). Chemokines
are produced in the brain by different populations of cells,
such as neurons and microglia. All chemokines mediate their
effects following their release as soluble molecules that generate a
chemotactic gradient for cell mobilization and migration, except
CX3C ligand 1 (CX3CL1; i.e., fractalkine) that mediates its effect
either as a soluble molecule or a membrane-anchored molecule
(Fernandez and Lolis, 2002). Depending on the nature of the
stimuli, the chemokines are functionally divided into two groups,
homeostatic, which are constitutively produced and contribute in
basal cell migration, and inflammatory, which are induced once
the inflammatory response is engaged (Sokol and Luster, 2015).
Microglia express a wide range of chemokine receptors with
different expression levels that are specie- and region-dependent,
namely CCL1 receptor (CCR1), CCR2, CCR3, CCR4, CCR5,
CCR6, CCR7, CXCR1, CXCR2, CXCR3, CXCR4, and CXCR5
(reviewed in Kettenmann et al., 2011). Chemokine receptors are
G protein-coupled receptors (GPCRs), which upon activation
modulate different downstream signaling pathways that lead to
the regulation of calcium (Ca2+) homeostasis, Rho GTPases
activity, and MAPK signaling pathway. The CCL2/CCR2, CCL5
[i.e., regulated on activation, normal T cell expressed and secreted
(RANTES)]/CCR5, and CX3CL1/CX3CR1 signaling pathways
play particularly important roles in microglial cell function.
Following TLR activation, CCL2 is produced by microglia,
thus acting in an autocrine and paracrine manner. In parallel,
the CCL2/CCR2 signaling pathway plays a central role in
regulating peripheral leukocyte recruitment and infiltration into
the brain during inflammatory reactions (El Khoury et al.,
2007). Similar to CCL2/CCR2 signaling pathway, CCL5/CCR5
signaling pathway is regulated in an autocrine and paracrine
manner. Activation of this signaling pathway has been reported
to suppress the production of major pro-inflammatory cytokines,
namely TNFα, IL1β, and IL6 (Gamo et al., 2008). On the
other hand, CX3CL1 is secreted essentially by neurons and
binds to its receptor CX3CR1 in microglia, thus acting as
messenger that is involved neuron-microglia communication.
The CX3CL1/CX3CR1 signaling pathway plays an important role
in regulating microglial dynamics andmigration, which is central
for surveying neuronal function through lifespan (Paolicelli et al.,
2014). In parallel, the CX3CL1/CX3CR1 signaling pathway has
been shown to control the microglial production of several
pro-inflammatory cytokines, namely TNFα, IL1β, and IL6
(Limatola and Ransohoff, 2014). Interestingly, inactivation of
both CCL5/CCR5 and CX3CL1/CX3CR1 signaling pathways
was found to impair microglial migration and communication
between neurons and microglia. This may result in excessive
inflammatory response and neuronal damage (Gamo et al., 2008;
Cho et al., 2011).
Neurotransmitter Receptor Signaling
Microglia express a wide range of different types of
neurotransmitter receptors that play central role in different
cell functions, namely by mediating the interaction and
crosstalk between microglia and neurons in physiological
and pathological conditions. Among these neurotransmitter
receptors, purinoceptors, glutamate receptors, cholinergic
receptors, adrenergic receptors, and dopamine receptors have
been shown to play essential roles in modulating microglial cell
activity (reviewed in Kettenmann et al., 2011). The purinoceptor
signaling pathways play a central role in microglial cell function
due to the biological significance of their natural ligands, the
nucleotides. The extracellular neuronal release of nucleotides,
such as ATP, ADP, uridine triphosphate (UTP), and UDP,
translates a major cell dysfunction that precedes or accompanies
cell death, which is perceived by microglia as alerting signals
(Illes and Alexandre Ribeiro, 2004; Burnstock and Verkhratsky,
2010). These extracellular nucleotides are recognized by several
purinoceptors, namely the metabotropic P1 adenosine receptors
GPCRs, ionotropic P2X purinoceptors (ligand-gated cationic
channels), and metabotropic P2Y purinoceptors (GPCRs;
reviewed in Kettenmann et al., 2011). These receptors have the
ability to modulate microglial mobility and shape (Xiang et al.,
2006; Färber et al., 2008), which may result in deep changes
in membrane current and Ca2+ homeostasis (Boucsein et al.,
2003; Light et al., 2006). Ca2+ homeostasis regulates several
downstream signaling pathways in microglia, including those
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involved in cell motility and phagocytosis (Hoffmann et al.,
2003). In addition, purinoceptors are able to modulate innate
immune functions in the CNS (reviewed in Kettenmann et al.,
2011).
Among the glutamate receptors expressed in microglia, the
ionotropic α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid (AMPA) receptor and the metabotropic glutamate receptors
(mGluRs) are the best characterized. These receptors are
activated by glutamate released from neurons and regulate Ca2+
homeostasis, NF-κB signaling pathway, and TNFα turnover
(Noda et al., 2000; Kaushal and Schlichter, 2008). The gamma-
aminobutyric acid (GABA) constitutes the major inhibitory
neurotransmitter in the brain (Harris and Allan, 1985). The
metabotropic G protein-coupled receptor GABAB type is
expressed in a subpopulation of microglia and modulates Ca2+
homeostasis and down regulates the release of IL6 (Kuhn et al.,
2004). α7 nicotinic (α7nAChRs) are the best characterized
acetylcholine receptors in microglia, which seem to have anti-
inflammatory effects (De Simone et al., 2005). Adrenergic
receptors regulate Ca2+ homeostasis and reduce the release of
TNFα, IL6, and NO by microglia (Färber et al., 2005). Functional
D1/2-like dopamine receptors have been identified in microglia
and they seem to modulate potassium (K+) homeostasis and
cytokine production (Färber et al., 2005). Recent experimental
findings have provided evidence that neurotransmitter signaling
pathways may result in microglial cell mobility (Fontainhas et al.,
2011).
TREM2 Receptor Signaling
Insights into the functions of triggering receptor expressed
on myeloid cells-2 (TREM2) receptor are recently emerging.
TREM2 receptor is mainly expressed in dendritic cells (DCs),
osteoclasts, and microglia (Colonna, 2003). It is a cell surface
receptor that belongs to the immunoglobulin (Ig) superfamily
family that is encoded by a gene cluster linked to major
histocompatibility complex (MHC). TREM2 is a transmembrane
receptor that lacks cytoplasmic signaling element, which is
replaced by a charged domain that stimulates its association
with other transmembrane adaptor proteins, namely DNAX-
activation protein-12 (DAP12; Colonna, 2003). The association
of both receptor triggers microglia immunoreceptor tyrosine-
based activation motif (ITAM) signaling pathway that leads
to cytoskeleton reorganization, chemokine production, and
phagocytosis stimulation, which is accompanied by a reduction
in pro-inflammatory cytokine and ROS generation (Fu et al.,
2014). Interestingly, the depletion of TREM2 in mice has
been shown to severely impair microglial cell response to
microenvironment stimuli, morphology, and migration, thus
outlining an important role of this receptor in microglial cells
(Rivest, 2015; Wang et al., 2015). Activation of TREM2 signaling
pathway is induced upon the biding of several charged lipid
derivatives, including phospholipids (Wang et al., 2015). More
precisely, TREM2 seems to act as a sensor for several anionic
and Zwitter-ionic lipids that are derived from the cell membrane
of neurons and glial cells, as lipid derivatives generated from
some organelles such as mitochondria failed to trigger TREM2
activation (Wang et al., 2015). TREM2 is able to bind the heat
shock protein-60 (Hsp60), which enhances phagocytosis by these
cells (Stefano et al., 2009).
A recent genome-wide association studies (GWAS) have
shown that a rare Arginine-47-Histidine (R47H) mutation
of TREM2 is associated with a substantial increase in the
risk of developing Alzheimer’s disease (AD; Jonsson et al.,
2013). The significance of this mutation has been recently
confirmed experimentally when TREM2 depletion in 5XFAD
mice significantly increased cerebral amyloid beta (Aβ) load
due to a dysfunctional response of microglia, which fail to
cluster around Aβ plaques and become apoptotic (Wang et al.,
2015). Importantly, in this study the authors demonstrated that
TREM2 acted as a sensor of several modified lipids known
to associate with fibrillar Aβ in lipid membranes and to be
exposed on the surface of damaged neurons, which is in
line with the implications of the R47H mutation that impairs
essentially TREM2 detection of lipid ligands (Wang et al.,
2015). However, the implication of the cerebral Aβ reduction on
cognition has not been addressed, thus the functional outcome
of the here above reported observations cannot be assessed
(Rivest, 2015).
Phosphatidylserine Receptor Signaling
Phosphatidylserine (PS) is a phospholipid that is normally
sequestered in the inner leaflet of plasma membrane, which
is exposed once cells are undergoing apoptosis (Martin et al.,
1995). The recognition of PS by specialized receptors (PSRs) is
crucial for an efficacious clearance of cell debris by specialized
phagocytes (Ravichandran, 2011). Microglia express several
specialized PSRs that directly bind PS, namely brain-specific
angiogenesis inhibitor-1 (BAI1), T-cell immunoglobulin mucin
receptor 1 (TIM1), and TIM4 (Ravichandran, 2011). In addition,
PSRs include some receptors that indirectly bind PS by using an
intermediate molecule, namely c-mer proto-oncogene tyrosine
kinase (MerTK) that uses growth arrest specific gene-6 (Gas6)
as a bridging molecule, and vitronectin receptors (i.e., αvβ3 or
αvβ5 integrins) that use milk fat globule-EGF factor 8 protein
(MFG-E8) as a bridging molecule (Ravichandran, 2011). The
direct and indirect recognition of PS by PSRs are crucial in
mediating apoptotic cell phagocytosis by microglia. Importantly,
the cooperation and activity coordination among these receptors
seem to be central in mediating an efficacious phagocytosis
(Mazaheri et al., 2014). For example, BAI1 has been reported to
be in charge of controlling the formation of phagosomes around
dying neurons and the transport of apoptotic cargos, while TIM4
is more involved in the downstream stabilization of phagosomes
(Mazaheri et al., 2014). However, both receptors are required to
mediate a successful engulfment of apoptotic neurons (Mazaheri
et al., 2014). Besides being central in microglial cell phagocytosis,
PSR activation is accompanied by a significant reduction in the
release of several pro-inflammatory molecules, such as TNFα,
IL1β, and NO (De et al., 2002).
Scavenger Receptor Signaling
Scavenger receptors (SRs) comprise structurally diverse cell
membrane receptors that have been shown to contribute to
several cell functions, namely adhesion, and uptake of negatively
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charged macromolecules, and oxidized or acetylated low-density
lipoprotein (LDL; Canton et al., 2013). Interestingly, several
classes of SRs are expressed in microglia and they play key
roles in innate immunity (Peiser et al., 2002). Among these
SRs, macrophage SR class AI (SR-AI), macrophage receptor
with collagenous structure (MARCO), SR-B3 (i.e., CD36),
macrosialin (i.e., CD68), and recently lectin-like oxidized low-
density lipoprotein receptor-1 (LOX1) have been reported to
play particularly important roles in microglial cell function. SR-
AI is a trimer integral glycoprotein composed of a cytosolic
tail, a transmembrane region, a spacer domain, α-helical coiled-
coil motif, collagen-like domain, and a cysteine-rich C-terminal
domain (Matsumoto et al., 1990). SR-AI seems to bind a
wide range of molecules, namely modified lipids and proteins,
polyribonucleotides, polysaccharides, and anionic phospholipids
(de Winther et al., 2000). SR-AI activation induces production
of a several inflammatory factors, namely TNFα, IL1β, IL-6,
and NO (Coller and Paulnock, 2001). Although MARCO is
a member of the SR-A family, this receptor binds additional
distinct ligands, outlining a larger role in regulating cell function
(Thakur et al., 2009). Indeed, MARCO activation triggers
microglial cytoskeleton reorganization, a mechanism that is
highly important in the process of phagocytosis and cell mobility
(Granucci et al., 2003). CD36 is a member of the SR-B family
that is abundantly expressed in microglia (Coraci et al., 2002).
It binds a wide range of ligands, such as native/oxidized LDL,
collagen, thrombospondin, oxidized phospholipids, and long-
chain fatty acids (Febbraio et al., 2001). Stimulation of CD36
signaling pathway enhances microglial cell phagocytosis and
production of pro-inflammatory cytokines, chemokines, and
ROS (El Khoury et al., 2003). CD36 has also been shown to
promote the formation of a TLR4/6 heterodimer and engagement
of both MyD88 and TRIF adaptors, which ultimately affect
microglia functions (Stewart et al., 2010). CD68 is a member of
the SR-B family that is characterized by the presence of a mucin-
like motif in the extracellular domain (Kobayashi et al., 2013).
It is mainly expressed on the membrane of intracellular late
endosomes under normal conditions, and its expression increases
following activation by oxidized LDL (Ramprasad et al., 1996).
CD68 is actively involved in microglial cell phagocytosis (Perego
et al., 2011). LOX1 is found as a homodimer on cell membrane,
and is the only identified member of SR-E family, which has been
shown to primarily bind and process oxidized LDL (Reiss et al.,
2009). Recent findings have revealed that the LOX1 structure
comprises a reactive backbone that can bind to a wide range of
ligands, including small molecules, such as acidic phospholipids,
and whole cell structure, such as apoptotic cells and bacteria
(Honjo et al., 2003). Although LOX1 was originally identified as
endothelial receptor for oxidized LDL (Sawamura et al., 1997),
recent reports showed that this receptor is also expressed on
microglial cells (Zhang et al., 2012). LOX1 activation induces
NF-κB signaling pathway that leads to the release of several pro-
inflammatory cytokines and ROS (Zhang et al., 2012; Li et al.,
2013). Importantly LOX1 is necessary for microglia for sensing
diffuse signals generated by neuronal injury, such as Hsp60
(Zhang et al., 2012). Hsp60 acts as an endogenous LOX1 ligand
(Delneste et al., 2002). These data suggest that LOX1 shares some
functional features with TLRs, outlining the implication of this
receptor in regulating brain immune responses. However, more
studies are warranted to better address this point.
Fc Receptor Signaling
Fc receptors (FcRs) belong to the immunoglobulin (Ig)
superfamily that binds the constant domain (Fc) of Ig.
They are subdivided into different subclasses based on their
binding to specific isotype classes and subclasses of Ig;
FcαR binds IgA, FcδR binds IgD, FcµR binds IgM, FcεR
binds IgE, and FcγR binds IgG (Daëron, 1997). Interestingly,
microglia express all FcR subgroups (Okun et al., 2010). The
cytoplasmic tail of FcRs could contain ITAM that provides a
positive signal for cell activation, and immunoreceptor tyrosine-
based inhibition motif (ITIM) that provides a negative signal
for cell activation. As such, the outcome of the receptor
aggregation is totally dependent on the immunoreceptor
tyrosine-based motif that was engaged (Daëron, 1997). Typically,
FcR activation results in their aggregation on cell surface, and
consequently triggering ITAM signaling pathway that leads
to the sequential activation of Src and Syk tyrosine kinases
(Daëron, 1997). This results in triggering several downstream
signaling pathways, such as NF-κB and MAPKs (Song et al.,
2004). This pathway triggers deep changes in microglial cell
function and behavior, mainly by modulating the release of
cytokines and by enhancing their phagocytic capacity (Okun
et al., 2010). In some cases, FcR aggregation on cell surface
triggers ITIM signaling pathway involving Src homology
region 2 domain-containing phosphatase-1 (SHP1) and Src
homology region 2 domain-containing inositol phosphatase-
1 (SHIP1), which is a potent inhibitory mechanism for
microglia (Billadeau and Leibson, 2002). In parallel, FcRs
have been shown to signal independently of their binding
to Ig. For instance, it has been reported that soluble FcRs
can modulate the release of some cytokines, such as TNFα
and IL6 (Okun et al., 2010). However, more studies are
warranted to better address the implication of this non-
Ig dependent signaling pathway in regulating microglial cell
function under both physiological and pathophysiological
conditions.
Siglec-3 Receptor Signaling
The sialic acid-binding immunoglobulin-type lectin-3 (Siglec-
3; i.e., CD33) is a type 1 transmembrane receptor that is
essentially expressed on the surface of cells that belong to the
myeloid lineage (reviewed in Crocker et al., 2007). CD33 is a
member of the CD33-related Siglecs, which has two extracellular
immunoglobulin domains (IgV/IgC2) that recognize sialic acid
residues of glycoproteins and glycolipids, and an intracellular
domain that contains ITIM in humans, or ITIM-like domain
in rodents (Crocker et al., 2007). ITIM and ITIM-like domains
act as docking sites or SHP1 and SHP2, via which CD33 and
CD33-related Siglecs execute several inhibitory functions on
cell adhesion, endocytosis, and cytokine release by immune
cells (Crocker et al., 2007). CD33 is expressed by microglia
in both the human and rodent brains, which upon activation
significantly reduces microglial cell phagocytic capacity (Griciuc
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et al., 2013). In addition, Siglec-E, a CD33-related Siglecs has
been recently shown to recognize neural glycocalyx, and to
inhibit the phagocytosis of neural debris by microglia in vitro
(Claude et al., 2013). Taken together, these reports clearly outline
the central role of CD33 and CD33-related Siglecs in acting as
regulatory receptors that tightly control the immune functions
of microglia under both physiological and pathophysiological
conditions. However, more studies are warranted in order to fully
address their role in the brain.
Miscellaneous Receptor Signaling
Microglia express several other set of receptors that contribute,
to different extents, in controlling and regulating their functions.
The complement receptors (CRs) play a central role in the
innate immune response (Crehan et al., 2012, 2013). Macrophage
colony-stimulating factor receptor (m-CSFR) stimulates the
phagocytic capacity of microglia, which is a critical mechanism
for the clearance of amyloid beta from the CNS (Boissonneault
et al., 2009). Sigma-1 receptor (S1R) is a membrane-associated
protein that binds endogenous monoamine molecules, which
affect Ca2+ homeostasis and suppress several key features of
microglia (Hall et al., 2009). In addition, the progesterone
receptor membrane component-1 (PGRMC1) has been recently
identified as the putative S2R binding site (Xu et al., 2011).
Interestingly, the S2R/PGRMC1 has been shown to be activity
involved in regulating microglial cell activity, which had
implications on neurite outgrowth (Bali et al., 2013). Finally, the
OX2 (CD200) cell membrane glycoprotein receptor (CD200R),
a member of the Ig superfamily, plays a role in controlling
microglial cell activity (Hoek et al., 2000).
The receptor for advanced glycation endproducts (RAGE) is
a multiligand receptor that belongs to the Ig superfamily, which
consists of an extracellular domain, a single transmembrane
domain and a cytosolic domain (Schmidt et al., 2001). It binds
to a wide range of ligands, such as advanced glycosylation
endproducts (AGE), S100/calgranulin family of proteins, and
high mobility group box-1 (HMGB1; Schmidt et al., 2001).
RAGE is expressed in microglia and induces NF-κB and
MAPK signaling pathway, which causes the release of several
pro-inflammatory cytokines, such as TNFα and IL1β (Fang
et al., 2010). Interestingly, RAGE mediates some of these
effects by interacting with the chemotaxic GPCRs, formyl
peptide receptor-1/2 (FPR1/2; Slowik et al., 2012). LDL related
receptor-1 (LRP1) is a cell membrane multiligand receptor
composed of an extracellular domain, a transmembrane domain
and an intracellular domain that contains two NPXY motif
copies involved in signal transduction (Herz and Strickland,
2001). LRP1 is an intriguing receptor due to its diverse
roles in multiple unrelated biological and cellular processes,
such as endocytosis, cell–cell communication, cytoskeleton
reorganization, intracellular signaling, lipid homeostasis, and
clearance of apoptotic cells (Lillis et al., 2008). LRP1 has an
extremely wide range of various ligands that include lipoproteins,
enzymes, protein complexes, endotoxins, viral proteins, and
apoptotic cells (Herz and Strickland, 2001; Gardai et al., 2005).
In parallel, LRP1 has been reported to interact with several
other membrane receptors, namely APP, platelet-derived growth
factor receptor-β (PDGFRβ), and β2 integrins, the latter been
implicated in LRP1-dependent cell migration (Ranganathan
et al., 2011). Microglia express a high level of LRP1, which
modulates several cell functions, such as phagocytosis and
migration, via the regulation of janus kinase (JAK)/signal
transducer and activator of transcription-1 (STAT1) and c-jun
N-terminal kinase-1/2 (JNK1/2) signaling pathways, respectively
(Pocivavsek et al., 2009; Jeon et al., 2012). Moreover, LRP1
signaling pathway provides potent anti-inflammatory processes
in microglia (Overton et al., 2007; Gaultier et al., 2008). Taken
together, these data outline an important role of LRP1 in
modulating the inflammatory response by innate immune cells
(Gorovoy et al., 2010; May et al., 2013).
ROLE OF MICROGLIA IN BRAIN
DISORDERS
Microglia have been shown to play important roles in brain
disorders. Here, we will discuss recent reports that outlined
a previously unrecognized role of these cells in different
pathological conditions.
Microglia in Multiple Sclerosis
Activation of microglia by lipopolysaccharide (LP) in vivo
prevents the accumulation ofmyelin debris and avoids premature
recruitment of oligodendrocyte (OD) progenitor cells (OPCs)
that are restricted to the border of demyelinated regions (Glezer
et al., 2006). The TLR4 ligand can induce these effects by
modulating expression of key genes involved in OPC recruitment
and differentiation, and in OD-mediated remyelination. In the
course of an ongoing innate immune response, cells that express
an oligodendrocyte transcription factor 1 (OLIG1), OLIG2,
and proteolipid protein (PLP) are normally recruited to the
demyelinated sites, whereas the presence of LPS increases the
expression of Pdgfrα (platelet-derived growth factor receptor, α
polypeptide). OLIG1, OLIG2, and Pdgfrα are key genes involved
in OPC mobilization and remyelination process. Accordingly,
LPS-induced microglia activation renders the brain tissue more
responsive tomyelin repair. This is also the case in response to the
TLR2 ligand zymosan, which substantially increases myelination
by transplanted OPCs in the retina (Setzu et al., 2006).
These data go against the proposed unfavorable role of
brain inflammation in demyelinating diseases, such as multiple
sclerosis (MS). However, although a single LPS injection
is probably not enough to cause neurodegeneration and
demyelination, long-term exposure to PAMPs, as it occurs during
severe meningitis, does have profound effects on the nervous
tissues. Indeed, OD death occurs in mixed cultures of glial
cells that are chronically exposed to LPS, and hypomyelination
occurs in developing white matter of immature rodents
following intracerebral LPS injection (Lehnardt et al., 2002).
Administration of LPS can also result in severe axonal and
neuronal loss following sub-threshold hypoxic–ischemic insult
that normally induces no discernable neuronal injury (Lehnardt
et al., 2003).
Microglia has been shown to actively contribute to brain
functioning by controlling the survival of developing neurons,
the maintenance of developing and mature synapses, the
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maturation of neuronal circuits, and the shaping of neuronal
connectivity (Tremblay et al., 2011). Importantly, microglia have
been shown to densely populate the neurogenic zones, such as the
subventricular zone (SVZ; Mosher et al., 2012), where they seem
to be more activated compared to non-neurogenic zones (Goings
et al., 2006). Interestingly, the presence of microglia in the SVZ
has been demonstrated to play an important role in promoting
neurogenesis and oligodendrogenesis via the production of
cytokines (Shigemoto-Mogami et al., 2014). Indeed, new reports
are suggesting that these innate immune cells play a central role
in myelin turnover under physiological and pathophysiological
conditions by phagocyting myelin debris and by influencing
oligodendrogenesis. For instance, when demyelination occurs in
the adult brain, microglia adopt a phenotype associated with
phagocytosis and the recruitment of OPCs (Jurevics et al., 2002;
Olah et al., 2012). The CX3CL1/CX3CR1 signaling pathway plays
a key role in this physiological interaction between microglia and
neurons (Paolicelli et al., 2011). CX3CL1 is secreted by neurons
and binds to its receptor, CX3CR1, which is exclusively expressed
on microglial cells in the healthy brain (Tremblay et al., 2011).
The CX3CL1/CX3CR1 axis plays a crucial role in regulating
microglial behavior and function, which decisively affect brain
functioning (Thériault et al., 2015).
In this regard, our group has recently demonstrated
that CX3CR1 depletion severely impeded myelin removal by
microglia, thus exacerbating myelin debris deposition and
spreading throughout the white matter of a mouse model of
progressive MS induced by cuprizone-based diet (Lampron
et al., 2015). This resulted in inefficient axonal remyelination
characterized by aberrant myelin patterns, which demonstrates
the critical role of CX3CR1 in promoting the clearance of
degenerated myelin by microglial cells (Lampron et al., 2015).
The knockout of CX3CR1 blocked the clearance of myelin
debris by microglia, which greatly affected the integrity of axons
and myelin sheaths, preventing proper remyelination. These
results highlight the crucial role played by CX3CR1 in myelin
removal and show that there can be no efficient remyelination
following a primary demyelinating insult if myelin clearance by
microglia is impaired. We also demonstrated a marked CCR2-
dependent infiltration of bone marrow-derived cells (BMDCs) in
demyelinating areas, but these cells do not impact demyelination
and remyelination.
Myelin removal is a critical step in the remyelination process
(Kotter et al., 2006). Cells of the mononuclear phagocytic
system, including monocyte-derived macrophages (MDM) and
microglia, are actively implicated in the clearance of myelin
debris. While monocytes do not migrate into the CNS
under normal conditions, we and others have shown the
specific infiltration of MDMs under pathological conditions
(Lampron et al., 2012, 2013b). Microglia and macrophages are
regarded as detrimental in MS and experimental autoimmune
encephalomyelitis (EAE), through their roles in autoimmunity
such as antigen presentation and pro-inflammatory cytokine
production. However, these noxious roles might mask other
beneficial properties. During demyelination, microglia exert a
phenotype associated with phagocytosis and the recruitment
of OPC. While recent work unraveled differences between the
roles played by blood-borne macrophages and microglia during
autoimmune-mediated demyelination (Yamasaki et al., 2014),
their respective functions in the process of primary de- and
remyelination of the brain were not completely understood until
recently.
Immunomodulators have been very efficient in the control
of acute demyelinating events in relapsing-remitting courses
of MS. However, these molecules have largely been ineffective
in alleviating chronic demyelination in progressive forms of
the disease, suggesting a primary neurodegenerative course
(Stys et al., 2012). As autoimmunity does not seem to play a
significant role in progressive forms of MS, a balance between
limiting demyelination and boosting remyelination of affected
sites must be reached for long-term therapeutic support of these
patients (Fox et al., 2012). However, the results reported in
our recent study propose important new concepts to take into
consideration: there can be no efficient remyelination if microglia
are unable to clear degenerate myelin from affected axons. As
such, an optimal treatment strategy could consist in boosting
microglial phagocytic processes while limiting inflammatory
responses, combined with agents targeting OD physiology.
Activated microglia may stimulate or block
oligodendrogenesis dependently on the nature of released
cytokines in an animal model of MS (Butovsky et al., 2006).
More precisely, high levels of IFNγ triggered microglial cells
to adopt a phenotype that impeded oligodendrogenesis, which
was associated with TNFα production. Whereas, IL-4 reversed
these effects, and the injection of IL-4-activated microglial
cells into the cerebrospinal fluid of mice resulted in increased
oligodendrogenesis in the spinal cord and improved clinical
outcomes (Butovsky et al., 2006). These results outlined a
previously unknown role of microglia in influencing endogenous
oligodendrogenesis via a selective production of cytokines
(Butovsky et al., 2006). It has been shown that microglia exhibit
a pro-inflammatory-like phenotype (i.e., M1 phenotype) during
the recruitment of OPCs, which was followed by a switch toward
an anti-inflammatory-like phenotype (i.e., M2 phenotype)
during the maturation of OPCs (Boven et al., 2006; Miron
et al., 2013). In addition, impaired myelin removal during
demyelination and myelin debris accumulation alter CNS
remyelination by affecting the differentiation of OPCs (Kotter
et al., 2005, 2006).
Microglia in Stress
The exposure to stress induces a profound shaping of
the neuronal network and deeply affects cognitive functions
(Blandino et al., 2006). Interestingly, recent reports are suggesting
that stress is causatively implicated in modulating the function
of microglial cells, which play important roles in shaping the
neuronal network in the adult brain. One of the initial reports
has shown that stress significantly increases the expression of
IL1β by microglial cells (Blandino et al., 2006). In addition,
stress has been shown to stimulate the capacity of microglia to
produce CCL2 and to increase the expression of TLR2 in these
cells (Shimoda et al., 2006). Interestingly, stress was reported
to influence microglial cell morphology as well. For instance,
stress induced a specific form of microglial remodeling, which is
translated by the formation of several new branching indicating
a higher ramification rate (Hinwood et al., 2013).
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Although the overwhelming experimental findings are
demonstrating that stress directly influences microglial cell
morphology and function (Walker et al., 2013), the underlying
mechanisms are still emerging. There is a wide range of evidence
demonstrating the ability of stress to significantly increase the
levels of circulating corticosterone (Ulrich-Lai and Herman,
2009). Steroid hormones, namely glucocorticoids, have been
shown to act as regulators of microglial inflammatory activity
(Sierra et al., 2008). Recently, the CX3CL1/CX3CR1 signaling
pathway has been shown to be implicated in regulating the
interaction between neurons and microglial in mice exposed
to stress conditions (Milior et al., 2016). Disturbing neuron-
microglia communication by deregulating CX3CL1/CX3CR1
signaling pathway prevented the effects of chronic unpredictable
stress on microglial function, neuronal plasticity, and depressive-
like behavior (Milior et al., 2016).
Interestingly, high level of stress exposure has been
linked to the severity of autism spectrum disorder (ASD)
in children (Pardo et al., 2005). In parallel, several line of
evidence demonstrated the presence of a sustained chronic
neuroinflammatory response associated with microglial cell
activation in the brain of children with ASD (Pardo et al.,
2005). Indeed, the expression levels of several pro-inflammatory
cytokines, such as IL6, IFNγ, and TNFα, were significantly
increased in the brains of ASD patients compared with the
controls (Vargas et al., 2005; Chez et al., 2007). It is supposed
that the sustained chronic activation of microglia triggers the
generation of a pro-inflammatory microenvironment, which
contributes to brain underconnectivity due to loss of synaptic
connections and neuronal death (Rodriguez and Kern, 2011).
Based on these findings, it is plausible to speculate that by
reducing brain inflammation it may be possible to improve
the efficacy of early behavioral and learning interventions, and
consequently enhance developmental outcomes of children
with ASD. As such, future studies, which aim at investigating
the effects of some pharmacological approaches that reduce
microglial cell activation to mitigate ASD symptoms, are
warranted.
CONCLUDING REMARKS
As mentioned above, microglia play an important role in
maintaining brain’s integrity and plasticity in normal conditions.
Under these conditions, they are highly ramified cells, which
continuously scan their microenvironment in order to sense the
presence of any endogenous or exogenous danger signals (e.g.,
damaged cells, microorganisms, etc...). Microglia rapidly respond
to these danger signals by orchestrating specific responses that are
totally dependent on the nature of such signals, which include
the release of cytokines and chemokines, and phagocytosis,
in order to clear the factors that trigger these danger cues
(Soulet and Rivest, 2008). Microglia react immediately to such
signals. However, “activated microglia” is an ambiguous term,
as recent findings have demonstrated that these cells are always
in an active state while surveying brain microenvironment.
This etymology rather outlines microglial cell activity shift
from surveying the microenvironment to executing specific
immune tasks with diverse functional outcomes. This shift is
translated by major changes in microglial cell phenotype under
pathological conditions. The actual suggested dichotomy in
different microglia phenotypes is mainly based on the M1/M2
activation states of macrophages. Depending on the nature of the
stimuli, two functionally different and extreme phenotypes have
been proposed for microglia, which are essentially based on in
vitro assessments. The classically activated M1 phenotype (i.e.,
pro-inflammatory phenotype), is induced by LPS stimulation,
and the alternatively activatedM2 phenotype (anti-inflammatory
phenotype), is induced by IL4/10 stimulation (Saijo and Glass,
2011). M1 microglia are characterized by the excessive release
of several pro-inflammatory cytokines, such as TNFα, IL1β,
and IL6, and have a prominent phagocytic capacity (Boche
et al., 2013). The alternatively activated M2 microglia are
characterized by the important release of several growth and
neurotropic factors, such as TGFβ, vascular endothelial growth
factor (VEGF), insulin-like growth factor-1 (IGF1), brain-derived
neurotrophic factor (BDNF), and nerve growth factor (NGF;
Saijo and Glass, 2011; Boche et al., 2013). As such, it has been
proposed that a shift toward a M1 phenotype exacerbates the
inflammatory response, while a shift toward a M2 phenotype
helps in tissue repair and healing (Heneka et al., 2013).
However, recent lessons from macrophages suggested that
the same cell has the potential to adopt M1 or M2 phenotype
based on either the nature of the stimuli and/or on the
original activation status of the cell before being exposed to the
stimuli (Mosser and Edwards, 2008). Based on these findings,
it has been suggested that it would be more appropriate to
consider the phenotype adopted by microglia to be a part
of a continuously evolving spectrum of phenotypes, which
is dependent on the specific spatiotemporal context under
which microglia were investigated (Weitz and Town, 2012).
It is noteworthy to mention that most of these studies were
performed in vitro using simple stimulus, which does not
translate the complexity of the microenvironment in which
microglia are present in vivo (Lampron et al., 2013a). In addition,
the implication of some indirect effectors in vivo, such as
the production of several bioactive molecules by neighboring
cells cannot be excluded. As such it is too simplistic to
categorize microglial activation into two functionally distinct
phenotypes, which depend on the nature of the cerebral
microenvironment.
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